Document:

EX-10.15

 Exhibit 10.15 

January 15, 2018 
 Deborah Tower 

[...***...] 
 Re:    Employment Terms

 Dear Deborah: 
 RENEO PHARMACEUTICALS, INC. (the
“Company”) is pleased to offer you the position of Senior Director, Finance & Administration on the following terms. 

You will be responsible for the duties that are normally associated with the position of Senior Director, Finance & Administration and will report to
the Chief Operating Officer of the Company. You will work at the Company’s corporate offices in San Diego. The Company may change your position, duties, and work location from time to time in its discretion. 

Your base salary will be $180,000 on an annualized basis, less payroll deductions and withholdings, paid on the Company’s normal payroll schedule. You
will be eligible for an annual discretionary bonus, with a target amount of such bonus of twenty percent (20%) of your then current Base Salary (the “Annual Bonus”). Whether you receive an Annual Bonus for any
given year, and the amount of such Annual Bonus, will be determined in the good faith discretion of the Company’s Board of Directors (the “Board”), based upon the Company’s and your achievement of
objectives and milestones to be determined on an annual basis by the Board. No Annual Bonus is guaranteed and, in addition to the other conditions for earning such compensation, you must remain an employee in good standing for the Company on the
scheduled Annual Bonus payment date in order to be eligible for any Annual Bonus. 
 During your employment, you will be eligible to participate in the
standard benefits plans offered to similarly situated employees by the Company from time to time, subject to plan terms and generally applicable Company policies. A full description of these benefits is available upon request. The Company may change
compensation and benefits from time to time in its discretion. 
 Subject to approval by the Company’s Board, the Company anticipates granting you an
option to purchase 105,074 shares of the Company’s common stock at the fair market value as determined by the Board as of the date of grant (the “Option”). The anticipated Option will be governed by the
terms and conditions of the Company’s 2014 Equity Incentive Plan, as amended (the “Plan”) and your grant agreement, and will include a four year vesting schedule, under which 25% of your Option will vest 12
months after the vesting commencement date, and 1/48th of the total shares will vest at the end of each month thereafter], until either the Option is fully vested or your continuous service (as defined in the Plan) terminates, whichever occurs
first. 
 As a Company employee, you will be expected to abide by Company rules and policies. As a condition of employment, you must sign and comply with
the attached Employee Confidential 

 
Information and Inventions Assignment Agreement which prohibits unauthorized use or disclosure of the Company’s proprietary information, among other obligations. 

In your work for the Company, you will be expected not to use or disclose any confidential information, including trade secrets, of any former employer or
other person to whom you have an obligation of confidentiality. Rather, you will be expected to use only that information which is generally known and used by persons with training and experience comparable to your own, which is common knowledge in
the industry or otherwise legally in the public domain, or which is otherwise provided or developed by the Company. You agree that you will not bring onto Company premises any unpublished documents or property belonging to any former employer or
other person to whom you have an obligation of confidentiality. You hereby represent that you have disclosed to the Company any contract you have signed that may restrict your activities on behalf of the Company. 

Normal business hours are from 9:00 a.m. to 5:00 p.m., Monday through Friday. As an exempt salaried employee, you will be expected to work additional hours as
required by the nature of your work assignments. 
 Your employment with the Company will be “at-will.”
You may terminate your employment with the Company at any time and for any reason whatsoever simply by notifying the Company. Likewise, the Company may terminate your employment at any time, with or without cause or advance notice. Your employment at-will status can only be modified in a written agreement signed by you and by an officer of the Company. 
 This offer
is contingent upon a reference check and satisfactory proof of your right to work in the United States. You agree to assist as needed and to complete any documentation at the Company’s request to meet these conditions. 

To ensure the rapid and economical resolution of disputes that may arise in connection with your employment with the Company, you and the Company agree that
any and all disputes, claims, or causes of action, in law or equity, including but not limited to statutory claims, arising from or relating to the enforcement, breach, performance, or interpretation of this Agreement, your employment with the
Company, or the termination of your employment, shall be resolved, to the fullest extent permitted by law, by final, binding and confidential arbitration conducted by JAMS or its successor, under JAMS’ then applicable rules and procedures for
employment disputes (available upon request and also currently available at http://www.jamsadr.com/rules-employment-arbitration/). You acknowledge that by agreeing to this arbitration procedure, both you and the Company waive the right to
resolve any such dispute through a trial by jury or judge or administrative proceeding. You will have the right to be represented by legal counsel at any arbitration proceeding. The arbitrator shall: (a) have the authority to compel
adequate discovery for the resolution of the dispute and to award such relief as would otherwise be permitted by law; and (b) issue a written statement signed by the arbitrator regarding the disposition of each claim and the relief, if any,
awarded as to each claim, the reasons for the award, and the arbitrator’s essential findings and conclusions on which the award is based. The arbitrator shall be authorized to award all relief that you or the Company would be entitled to seek
in a court of law. The Company shall pay all JAMS arbitration fees in excess of the administrative fees that you would be required to pay if the dispute were decided in a court of law. Nothing in this letter

  
 2 

 
agreement is intended to prevent either you or the Company from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such arbitration. 

This letter, together with your Employee Confidential Information and Inventions Assignment Agreement, forms the complete and exclusive statement of your
employment agreement with the Company. It supersedes any other agreements or promises made to you by anyone, whether oral or written. Changes in your employment terms, other than those changes expressly reserved to the Company’s discretion in
this letter, require a written modification signed by an officer of the Company. If any provision of this offer letter agreement is determined to be invalid or unenforceable, in whole or in part, this determination shall not affect any other
provision of this offer letter agreement and the provision in question shall be modified so as to be rendered enforceable in a manner consistent with the intent of the parties insofar as possible under applicable law. This letter may be delivered
via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act or other applicable law) or other transmission method and shall be deemed to have been
duly and validly delivered and be valid and effective for all purposes. 
 Please sign and date this letter, and the enclosed Employee Confidential
Information and Inventions Assignment Agreement and return them to me by January 17, 2018, if you wish to accept employment at the Company under the terms described above. If you accept our offer, your starting date will be January 1,
2018. 
 We look forward to your favorable reply and to a productive and enjoyable work relationship. 

 

	
	 Sincerely,

	
	 /s/ Wendy Johnson

	 Wendy Johnson, Chief Operating Officer

  

			
	 Understood and Accepted:

 
	  	

							
	 /s/ Deborah Tower
	 		 		 	1/16/18
	 Deborah Tower
	 		 		 	Date

 Attachment: Employee Confidential Information and Inventions Assignment Agreement 

  
 3EX-10.16

 Exhibit 10.16 

RENEO PHARMACEUTICALS, INC. 

February 12, 2018 
 Michael Grey 

[...***...] 
 Re:    Position as Executive
Chairman of Reneo Pharmaceuticals, Inc. 
 Dear Mr. Grey: 

This letter confirms, on behalf of Reneo Pharmaceuticals, Inc. (the “Company”), the terms on which you will continue to
serve as Executive Chairman of the Company. 
 As Executive Chairman, you will work closely with the Company’s Board of Directors (the
“Board”) and the executive team of the Company to further the goals and objectives of the Company, consistent with the usual and customary duties of an executive chairman. 

As compensation for your service as Executive Chairman, you will be paid a fee of $200,000.00 per year (the “Annual
Fee”), payable in equal monthly installments, and you will be eligible for an annual discretionary bonus, with a target equal to forty percent (40%) of your Annual Fee (the “Annual Bonus”). Whether you receive an
Annual Bonus for any given year, and the amount of any such Annual Bonus, will be determined in the good faith discretion of the Board (or the Compensation Committee thereof), based upon the Company’s and your achievement of objectives and
milestones to be determined on an annual basis by the Board (or Compensation Committee thereof). No Annual Bonus is guaranteed and, in addition to the other conditions for earning such compensation, you must remain a service provider of the Company
in good standing on the scheduled Annual Bonus payment date in order to be eligible for any Annual Bonus. 
 As additional compensation, on
January 31, 2018, the Board approved, contingent and effective upon (i) receipt by the Company of a final 409A valuation report performed by an independent valuation firm and an affirmative determination by the Board of the fair market
value of the Company’s Common Stock (the “Common Stock”) and (ii) you providing services to the Company at such time, the grant of an option to you to purchase 525,370 shares of Common Stock with an exercise price
per share equal to the fair market value of a share of Common Stock on the date such grant becomes effective (the “Grant”). The Grant is governed by the terms and conditions of the Company’s 2014 Equity Incentive Plan,
as amended (the “Plan”), and your grant agreement, and includes a vesting schedule under which one-fourth (1/4th) of the shares subject to the Grant vest on the one year anniversary of
January 1, 2018 and the balance of the shares vest in a series of thirty-six (36) successive equal monthly installments thereafter, subject to your Continuous Service (as defined in the Plan) as of
each such date. In the event that you (i) are terminated by the Company without Cause (as defined in the Plan) or (ii) resign for Good Reason (as defined below), the vesting of the Grant shall be accelerated in full. “Good
Reason” for your resignation means the occurrence of any of the following events, conditions or actions taken by the Company without Cause and without your consent: (i) a 

  
 1. 

 
material reduction of your Annual Fee, which is a reduction of at least ten percent (10%) of your Annual Fee; or (ii) a material reduction in your authority, duties or responsibilities;
provided that if your principal place of providing services is your personal residence, this clause (iv) shall not apply; provided, however, that in each case above, in order for your resignation to be deemed to have been for Good
Reason, you must first give the Company written notice of the action or omission giving rise to “Good Reason” within thirty (30) days after the first occurrence thereof; the Company must fail to reasonably cure such action or omission
within thirty (30) days after receipt of such notice (the “Cure Period”), and your resignation must be effective not later than thirty (30) days after the expiration of such Cure Period. 

The Company will also reimburse you for reasonable
out-of-pocket expenses incurred in connection with your service as Executive Chairman in accordance with the Company’s established reimbursement policies. 

You agree to continue to abide by the terms and conditions of that certain Consultant Proprietary Information and Inventions Agreement between
you and the Company dated December 20, 2017, as may be amended from time to time (the “PIIA”). You also represent to the Company that your service as Executive Chairman will not conflict with any other obligations that
you have to third parties. 
 Either party may terminate this letter for convenience, for any or no reason, at any time upon ninety
(90) days prior written notice to the other party. 
 This letter, along with the PIIA and the documentation reflecting the Grant
referred to herein, constitute the entire agreement between you and the Company regarding the subject matter hereof. This letter supersedes any other agreements or promises made to you by anyone, whether oral or written, and it may only be modified
in a writing signed by you and a duly authorized officer of the Company. 
 If the terms of this letter are acceptable to you, please sign
and date this letter below and return it to me, retaining a copy for your records. 
  

	
	Very truly yours,
	
	RENEO PHARMACEUTICALS, INC.
	
	/s/ Niall O’Donnell
	Niall O’Donnell, Ph.D.
	President and Chief Executive Officer

  

	
	Accepted and agreed:
	
	/s/ Michael Grey
	Michael Grey
	
	Date:    02/12/2018

  
 2.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00324-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00324-of-00352.parquet"}]]